In this presentation we show the advantages of CRS + HIPEC vs CRS alone for the treatment of stage III ovarian cancer.
Ovarian cancer is one of the most prevalent malignancies worldwide, presenting with advanced disease and peritoneal spread in a significant number of cases. Disease burden and quality of life impairment are significant in a huge proportion of women around the world.
Primary treatment with Cytoreductive Surgery plus HIPEC is emerging as the best treatment option as supported by well conducted studies which we present.
Share it with your network and help spread clinical knowledge.
